<div id="readability-page-1"><div><p>Tenet Healthcare (THC) has reported solid top line and bottom line figures for FY 2025 so far, with Q3 revenue at US$5.3 billion and basic EPS of US$3.89, alongside trailing 12 month EPS of US$14.70 on revenue of US$20.8 billion. The company’s quarterly revenue moved from US$5.1 billion in Q2 2024 to US$5.3 billion in Q3 2025. Over the same period, basic EPS shifted from US$2.66 in Q2 2024 to US$3.89 in the latest quarter and ranged between US$3.16 and US$4.93 during the intervening reporting periods. These results are likely to draw investor attention to how profit margins are holding up across this stretch of performance.</p> <p>See our full analysis for Tenet Healthcare.</p><p>With the latest earnings numbers in place, the next step is to compare them with the existing narratives around Tenet Healthcare to evaluate which views on its growth, risks, and profitability remain relevant and which ones may now appear outdated.</p> <p>See what the community is saying about Tenet Healthcare</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5171f3ad-ad64-48de-9160-01875eb456d0/chart/earnings-and-revenue-history?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5171f3ad-ad64-48de-9160-01875eb456d0/chart/earnings-and-revenue-history"/><figcaption>NYSE:THC Earnings &amp; Revenue History as at Feb 2026</figcaption></figure> <h2>Margins Compressed, Profit Still Positive</h2> <ul> <li>Tenet is earning a 6.5% net profit margin on about US$20.8b of trailing 12 month revenue, compared with 14.9% a year earlier, while trailing net income excluding extra items sits at US$1.4b.</li> <li>Bulls highlight margin potential from high acuity outpatient growth, but the margin move from 14.9% to 6.5% means the bullish case leans heavily on future execution rather than what the latest year shows.     <ul> <li>The bullish narrative points to USPI ambulatory margins near 38%. At the group level, however, the 6.5% margin shows those high margin areas are not fully lifting overall profitability.</li> <li>Bullish analysts also talk about cost control and digital tools supporting margins. The most recent 12 month profit trend is weaker than the 5 year profit growth of 33.2% per year that they often point to.</li> </ul> </li> </ul> <p>Investors who think those high margin outpatient platforms can gradually pull the overall margin closer to the bullish story may want to see how that thesis is laid out in full in the dedicated bull case for Tenet Healthcare: <strong>🐂 Tenet Healthcare Bull Case</strong></p> <h2>Debt Coverage And Earnings Pressure</h2> <ul> <li>The company is flagged for weak debt coverage by operating cash flow and forecasts in the supplied data show earnings expected to decline about 3.6% per year over the next three years.</li> <li>Bears argue that these balance sheet and earnings pressures limit room for error, and the current 6.5% margin plus modest trailing revenue growth of roughly 3% a year leave less cushion if those forecasts play out.     <ul> <li>The cautious view focuses on high debt levels and industry wide labor cost pressure, and the weak cash flow coverage metric directly ties into that concern about flexibility.</li> <li>Bearish analysts also assume margins could move from 7.1% to 5.0% over three years. This lines up with the already lower trailing margin and the slower revenue growth versus the 10.4% US market benchmark.</li> </ul> </li> </ul> <p>If you are weighing those debt and margin risks more heavily, it is worth seeing how skeptics connect the dots between the 3.6% expected earnings decline and Tenet Healthcare's current profile: <strong>🐻 Tenet Healthcare Bear Case</strong></p> <h2>Low P/E Against DCF Fair Value</h2> <ul> <li>At a share price of US$226.35, Tenet is trading on a 14.7x P/E compared with a peer average of 25.6x and an industry average of 23.1x, and well below the provided DCF fair value of about US$1,151.29.</li> <li>Supporters see this valuation gap as attractive, but both bullish and bearish narratives point out that future earnings in their scenarios are lower than the current US$1.5b level, so the low P/E and gap to DCF fair value are being weighed against forecasts of shrinking profits.     <ul> <li>Bullish analysts model earnings of about US$1.4b by 2028 with profit margins moving from 7.1% to 5.8%. This relies on the P/E moving to 15.1x to reach their 237.00 price target.</li> <li>Bearish analysts model earnings of about US$1.1b by 2028 and an 11.9x P/E to justify the same 237.00 target. Both sides are effectively using lower earnings than today while still arguing the current 14.7x multiple is not demanding.</li> </ul> </li> </ul> <h2> Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Tenet Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>See the numbers a different way? Take a couple of minutes to test your own view and turn it into a clear narrative with Do it your way</p> <p>A great starting point for your Tenet Healthcare research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.</p> <h2>See What Else Is Out There</h2> <p>Tenet Healthcare combines a compressed 6.5% net margin with weak debt coverage by operating cash flow, leaving less room if earnings or costs move against it.</p> <p>If that balance sheet pressure worries you, take a look at our solid balance sheet and fundamentals stocks screener (45 results) today to focus on companies with stronger financial cushions backing their earnings stories.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Tenet Healthcare might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

<p>Tenet Healthcare (THC) reported Q3 revenue of $5.3 billion and EPS of $3.89, showing growth from Q2 2024. However, net profit margin has decreased from 14.9% to 6.5%, raising concerns about future profitability. Analysts are divided; bullish views focus on outpatient growth potential, while bearish perspectives highlight high debt and declining earnings forecasts. Tenet's P/E ratio of 14.7x is below industry averages, suggesting a valuation gap, but both sides anticipate lower future earnings. Investors are encouraged to monitor the evolving narratives around Tenet Healthcare.</p>

Simplywall

VG Health

iShares Global Healthcare

Tenet Healthcare Q3 Margin Compression Challenges Bullish Profitability Narratives